Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JS 207

Next Previous
Drug Profile

JS 207

Alternative Names: JS-207

Latest Information Update: 20 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DotBio
  • Developer Shanghai Junshi Biosciences; University of Hong Kong
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Liver cancer; Lung cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 29 Jun 2026 Phase-II clinical trials in Nasopharyngeal cancer (Recurrent, Metastatic disease, Second-line therapy or greater, Combination therapy) in Hong Kong (IV) (NCT07690787)
  • 29 Jun 2026 Phase-II clinical trials in Nasopharyngeal cancer (Recurrent, Metastatic disease, Second-line therapy or greater, Monotherapy) in Hong Kong (IV) (NCT07690787)
  • 30 Apr 2026 Preliminary efficacy and adverse events data from a phase II trial in Colorectal cancer released by Junshi Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top